vericiguat   Click here for help

GtoPdb Ligand ID: 10010

Synonyms: BAY-1021189 | MK-1242 | Verquvo®
Approved drug
vericiguat is an approved drug (EMA & FDA (2021))
Compound class: Synthetic organic
Comment: Vericiguat is a novel oral soluble guanylate cyclase (sGC) stimulator [4]. It was initially developed for potential to reduce mortality and morbidity associated with chronic heart failure with reduced ejection fraction.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 146.86
Molecular weight 426.14
XLogP 2.36
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COC(=O)Nc1c(N)nc(nc1N)c1nn(c2c1cc(F)cn2)Cc1ccccc1F
Isomeric SMILES COC(=O)Nc1c(N)nc(nc1N)c1nn(c2c1cc(F)cn2)Cc1ccccc1F
InChI InChI=1S/C19H16F2N8O2/c1-31-19(30)25-14-15(22)26-17(27-16(14)23)13-11-6-10(20)7-24-18(11)29(28-13)8-9-4-2-3-5-12(9)21/h2-7H,8H2,1H3,(H,25,30)(H4,22,23,26,27)
1. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G et al.. (2020)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med, 382 (20): 1883-1893. [PMID:32222134]
2. Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B et al.. (2018)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
JACC Heart Fail, 6 (2): 96-104. [PMID:29032136]
3. Butler J, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD et al.. (2019)
Rationale and Design of the VITALITY-HFpEF Trial.
Circ Heart Fail, 12 (5): e005998. [PMID:31096775]
4. Follmann M, Ackerstaff J, Redlich G, Wunder F, Lang D, Kern A, Fey P, Griebenow N, Kroh W, Becker-Pelster EM et al.. (2017)
Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
J Med Chem, 60 (12): 5146-5161. [PMID:28557445]
5. Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L et al.. (2021)
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
JAMA Cardiol, 6 (6): 706-712. [PMID:33185650]
6. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET et al.. (2014)
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Eur J Heart Fail, 16 (9): 1026-38. [PMID:25056511]